We provide independent evidence in support of a recent finding by Craddock et al. 1 that variation in g-aminobutyric acid (GABA) A receptor genes is selectively associated with one component of the bipolar disorder (BD) phenotype, that is schizophrenia-like psychotic symptoms. The support is at a system-wide level and the pattern of genetic variation was not identical to that observed in the Craddock sample.
Although the GABAergic system, the major inhibitory neurotransmission system in the central nervous system, has been implicated in the etiology of BD, genetic association findings have been inconsistent. 2 One of the most strongly associated polymorphisms in the recent Wellcome Trust Case Control Consortium genome-wide association study of BD (1868 cases, 2938 controls) 3 is located in the GABRB1 gene, which encodes the GABA A receptor b1 subunit. The consortium conducted a further analysis to reduce biological heterogeneity. In this second analysis, the strongest signal at this polymorphism was found in the subsample meeting Research Diagnostic Criteria 4 for schizoaffective, bipolar type (SABP) (n = 279). Association signals were also found in the SABP subsample at GABRA4, GABRB3, GABRA5, and GABRR3 (experiment-wide P = 6.6 Â 10
À5
). This provided strong, independent evidence in support of the hypothesis that variation in other GABA A receptor genes is associated with risk for the SABP phenotype. No association was found with schizophrenia.
We aimed to replicate these findings in our German samples using the set-based approach. A total of 682 BD inpatients, 480 schizophrenia inpatients, and 1300 controls were included. All participants had been earlier genome-wide association study genotyped 5 using the Illumina HumanHap550v3 BeadArray. These data were subjected to strict quality control procedures, as described elsewhere. 5 Patients had been diagnosed according to DSM-IV 6 and the BD sample was divided into SABP (n = 352) and non-SABP (n = 330) cases according to Research Diagnostic Criteria on the basis of the Operational Criteria Checklist (OPCRIT v3.32). 7 Using Research Diagnostic Criteria, SABP was scored as being present if one or more of the 23 OPCRIT items (no. 54-77) indicating the life-time presence of abnormal beliefs, ideas, or perceptions occurred.
We searched Entrez Gene (NCBI build 36.3: http:// www.ncbi.nlm.nih.gov/gene/) for single-nucleotide polymorphisms across the 19 GABA A receptor genes and identified 362 that were within our genome-wide association study dataset. To reduce redundancy, we used the HaploView 8 (v4.1) implementation of de Bakker's tagger with r 2 set to 0.8 and obtained a final reduced marker set of 276 single-nucleotide polymorphisms. Table 1 shows their distribution across the 19 GABA A receptor genes.
We used the set-based test (with default options and 10 6 permutations), as implemented in PLINK 9 (v1.0.6), to test for association between the SABP cases and the whole set of these GABA A receptor gene variants (that is a system-wide test), as described by Craddock et al.
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We also performed gene-wide association testing for each gene.
In a system-wide replication of the earlier report, we observed significant association with the SABP cases when compared with controls (P = 0.00315). Gene-wide significant associations were observed for GABRA1 (P = 0.01647), GABRB2 (P = 0.00022), and GABRG2 (P = 0.01364). This combination of genes codes for the major GABA A receptor subunit in the mammalian brain. 2 Again replicating the earlier findings, we found (a) no association between the BD-non-SABP cases and controls; (b) no association between the schizophrenia cases and controls; and (c) a significant difference when our SABP cases were compared with the BD-non-SABP cases (P = 0.009).
The pattern of results at the system-wide level of testing is an exact and independent replication of that reported by Craddock et al. 1 However, the genes showing gene-wide levels of significance in the two studies were not identical.
Given the small estimated effect sizes and the modest sample size, there is very low power to replicate specific allele or gene effects. The rationale for undertaking system-wide testing was the expectation that, assuming that several (perhaps many) variants in the GABAergic system contribute to the etiology of the phenotype, a test that effectively 'pools' variation across the system is likely to have greater power than testing any single variant. 10 Despite this, we note that single-nucleotide polymorphisms from three out of five genes showing gene-wide significance in the earlier study (GABRB1, GABRA4, and GABRB3) showed nominal significance in the current dataset (Table 1 ). This suggests that replication at a gene-wide level may be possible with larger samples.
Our findings replicate those of Craddock et al. 1 and suggest that variation at GABA A receptor genes influences a specific psychiatric phenotype. Our results provide further support for the usage of genotype-phenotype dissection and the testing of specific biological hypotheses in the disentanglement of complex categorical diagnostic systems.
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2 Diet may also influence inflammation: a healthy dietary pattern rich in fruit, vegetables and olive oil, such as the Mediterranean diet, is associated with lower levels of inflammatory markers, perhaps because of the anti-inflammatory properties of antioxidants. 3 We examined (1) whether older individuals with depressive symptoms are more likely to develop a pro-inflammatory state and (2) whether such an excess risk of developing a pro-inflammatory state is lower in those who have a healthy (Mediterranean-style) diet. We tested this hypothesis using data from the InCHIANTI study, 4 a prospective population-based study of older persons in Tuscany (Italy). Participants were evaluated at enrollment (1998) (1999) ) and again at 3-and 6-year follow-up visits. Depressive symptoms were assessed at baseline with the Center for Epidemiologic Studies-Depression scale (CES-D). Adherence to the Mediterranean diet was assessed at baseline by a well-validated dietary questionnaire and a Mediterranean Diet Score (0-9, higher score indicating better adherence) was computed according to Trichopoulou et al. 5 Levels of interleukin-6 (IL-6) and C-reactive protein (CRP) were assessed at baseline, 3-and 6-year follow-up. The sample for the present analyses consisted of 793 participants aged X65 years with baseline data on depressive symptoms and inflammatory markers and at least one follow-up measure for each inflammatory marker. At enrollment, depressed (CESD X20) participants were older, more often women and sedentary, had lower level of physical functioning, took more medications and were less adherent to a Mediterranean-style diet. The longitudinal association between depressive symptoms and inflammatory markers was estimated using random coefficient analyses with random intercept and slopes. After adjustment for age, sex, physical activity, lower extremity function, number of medications, use of antidepressants and NSAIDs, CES-D scores (per s.d. increase) were associated with higher IL-6 increase over time, but not with CRP change. A significant depression*time effect (b = 0.09, s.e. = 0.02, P < 0.0001) indicated that higher depressive symptoms were associated with a steeper IL-6 increase over time. To examine the moderation effect of a healthy diet, we entered interaction terms depression*diet*time to the models including the interactions terms nested within this interaction. The interaction term was significant only in analysis focusing on IL-6 (P = 0.01). To further illustrate the interaction, the Mediterranean diet score was dichotomized around the median and the analyses were stratified by healthy diet status. Figure 1 shows that the unadjusted mean change in IL-6 levels after 6 years of follow-up differed significantly across depression and diet groups. Mean increase in IL-6 levels was higher among the depressed non-adherent to a healthy diet than in all other groups. Higher depressive symptoms were associated with a major increase in IL-6 levels over time in participants nonadherent to a healthy diet (b = 0.13, s.e. = 0.03, P < 0.0001), but not in those adherent (b = 0.04, s.e. = 0.03, P = 0.17), after adjustment for confounders. Similar results were obtained repeating all analyses using the clinical cutoff of 20 points on the CES-D. Taken together, these findings indicate that in older persons depressive symptoms are associated with increased inflammation over time, and that a healthy diet can buffer the effect of depression on inflammation. This interaction could be explained by shared biological pathways, such as the opposite modulation exerted by stress or antioxidants on transcription factor nuclear factor kappa B, which upregulate pro-inflammatory cytokines, 6, 7 or the accumulation promoted by depression and unhealthy diet of visceral fat, which in turn promotes inflammation directly or through other mechanisms such as hypothalamic-pituitary-adrenal axis dysregulation. 8 Moreover, depression and diet likely have a bidirectional
